The prognostic value of CDX2 in colorectal cancer: a meta- analysis

被引：0

作者：

Yu, Hongbin ^{[1
]}

Zhang, Heng ^{[2
]}

Cao, Qixin ^{[3
]}

Zhu, Wei ^{[1
]}

机构：

[1] First Peoples Hosp Huzhou, Dept Gen Surg, Huzhou, Zhejiang, Peoples R China

[2] Cent Hosp Lishui, Dept Gen Surg, Lishui, Zhejiang, Peoples R China

[3] Huzhou Hosp Tradit Chinese Med, Dept Surg, Huzhou, Zhejiang, Peoples R China

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2016年 / 9卷 / 08期

关键词：

CDX2; colorectal cancer; prognosis; meta-analysis; INTESTINAL DEVELOPMENT; POOR-PROGNOSIS; EXPRESSION; TRANSCRIPTION; CARCINOMA; PHENOTYPE; SURVIVAL; CELLS;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Caudal-type homeodomain transcription factors 2 (CDX2) acts as an intestine-specific transcription factor is essential for intestinal differentiation and development, which shows a low expression in colorectal cancer tissues. However, the prognostic role of CDX2 in colorectal cancer remains controversial. Here, a meta-analysis of eight published studies containing 2547 patients was conducted to evaluate the prognostic value of CDX2 in colorectal cancer by calculating the hazard ratio (HR) and its 95% confidence interval (CI). The summary results revealed that the low expression of CDX2 was association with poor prognosis of OS (HR=1.99, 95% CI: 1.31-3.02) and DFS (HR=1.81, 95% CI: 1.08-3.05). Subgroup analysis showed decreased CDX2 was a significant prognostic marker in Asian patients (HR= 2.66, 95% CI: 1.38-5.13), but not in Caucasian (HR= 1.56, 95% CI: 0.94-2.59). This meta-analysis demonstrated that CDX2 could act as a significant biomarker in the prognosis of colorectal cancer.

引用

页码：15955 / 15960

页数：6

共 50 条

[41] CDX2 is mutated in a colorectal cancer with normal APC/β-catenin signaling
Luis T da Costa
Tong-Chuan He
Jian Yu
Andrew B Sparks
Patrice J Morin
Kornelia Polyak
Steve Laken
Bert Vogelstein
Kenneth W Kinzler
Oncogene, 1999, 18 : 5010 - 5014
[42] CDX2 is an amplified lineage-survival oncogene in colorectal cancer
Salari, Keyan
Spulak, Mary E.
Cuff, Justin
Forster, Andrew D.
Giacomini, Craig P.
Huang, Stephanie
Ko, Melissa E.
Lin, Albert Y.
van de Rijn, Matt
Pollack, Jonathan R.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (46) : E3196 - E3205
[43] CDX2 is mutated in a colorectal cancer with normal APC/β-catenin signaling
da Costa, LT
He, TC
Yu, J
Sparks, AB
Morin, PJ
Polyak, K
Laken, S
Vogelstein, B
Kinzler, KW
ONCOGENE, 1999, 18 (35) : 5010 - 5014
[44] Regulation of CDX2 in colorectal cancer via methylation and histone deacetylation?
Uth, K.
Lugli, A.
Dawson, H.
Tschan, M.
Zlobec, I.
VIRCHOWS ARCHIV, 2017, 471 : S186 - S186
[45] CDX2 Expression in Metastatic Colorectal Adenocarcinoma
Gohlke, Amanda
Contos, Melissa
Fielden, Rachel B.
Idowu, Michael
LABORATORY INVESTIGATION, 2018, 98 : 265 - 265
[46] Pattern of expression of CDX2 in colorectal cancer and its role in prognosis
Singh, Jagdeep
Rajesh, N. G.
Dubashi, Biswajit
Maroju, Nanda Kishore
Ganesan, Prasanth
Matta, Kiran Kumar
Charles, I
Kayal, Smita
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (09) : S420 - S427
[47] CDX2 as a Prognostic Marker in Gastric Adenocarcinoma
Masood, Muhammad A.
Yusuf, Muhammed A.
Loya, Asif
LABORATORY INVESTIGATION, 2016, 96 : 186A - 186A
[48] CDX2 as a Prognostic Marker in Gastric Adenocarcinoma
Masood, Muhammad A.
Yusuf, Muhammad A.
Loya, Asif
MODERN PATHOLOGY, 2016, 29 : 186A - 186A
[49] CDX2 Expression in Metastatic Colorectal Adenocarcinoma
Gohlke, Amanda
Contos, Melissa
Fielden, Rachel B.
Idowu, Michael
MODERN PATHOLOGY, 2018, 31 : 265 - 265
[50] Prognostic value of microRNAs in colorectal cancer: a meta-analysis
Gao, Song
Zhao, Zhi-Ying
Wu, Rong
Zhang, Yue
Zhang, Zhen-Yong
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 907 - 929

← 1 2 3 4 5 →